Trial Profile

A Phase 1 Study of the Safety and Pharmacokinetics of Single Doses of Octreotide Administered Orally Via the RaniPill™ Capsule in Healthy Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 12 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Octreotide (Primary) ; Octreotide
Indications Acromegaly; Diarrhoea
Focus Adverse reactions; First in man
Sponsors Rani Therapeutics

Most Recent Events

08 Jun 2023 According to a Rani Therapeutics media release, the company announced that the late-breaking abstract has been selected for poster presentation at the American Diabetes Association's (ADA) Scientific Sessions taking place on June 23 - 26, 2023 in San Diego, CA.
30 Jan 2020 According to a Rani Therapeutics media release, the study successfully achieved both its primary and secondary endpoints.
30 Jan 2020 Results presented in a Rani Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com